K. Subramaniam

发表

Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease

K. Subramaniam, K. Fallon, T. Ruut, 2015, Alimentary pharmacology & therapeutics.

Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors

K. Subramaniam, B. Shadbolt, P. Pavli, 2015, Internal medicine journal.

Risk of non‐melanoma skin cancer with thiopurine use in inflammatory bowel disease

K. Subramaniam, P. Pavli, 2012, Journal of gastroenterology and hepatology.

Severe drug‐induced hypersensitivity syndrome with a shared HLA‐B allele

K. Subramaniam, D. Nolan, G. Macquillan, 2012, The Medical journal of Australia.

BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor-α inhibitors

K. Subramaniam, B. Shadbolt, F. Nordin, 2022, European journal of gastroenterology & hepatology.

Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes.

Steven J Brown, B. Bibby, M. Kamm, 2019, Inflammatory Bowel Diseases.

The significance of ANCA positivity in patients with inflammatory bowel disease.

K. Subramaniam, Katrina L. Randall, C. Hawkins, 2019, Pathology.

Paradoxical psoriasiform reactions of anti‐tumour necrosis factor therapy in inflammatory bowel disease patients

K. Subramaniam, P. Pavli, Andrew Miller, 2017, Internal medicine journal.

Hepatitis B status in migrants and refugees: increasing health burden in Western Australia

K. Subramaniam, S. Hopkins, J. Flexman, 2012, Internal medicine journal.

Two rare cases of Epstein–Barr virus‐associated lymphoproliferative disorders in inflammatory bowel disease patients on thiopurines and other immunosuppressive medications

M. Corbett, K. Subramaniam, P. Pavli, 2013, Internal medicine journal.

Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: A review

K. Subramaniam, P. Pavli, J. D’Rozario, 2013, Journal of gastroenterology and hepatology.

The issue is tissue

K. Subramaniam, C. Siah, S. Fermoyle, 2010, Gut.

Safe and effective: anti‐tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis

K. Subramaniam, J. Platten, P. Pavli, 2016, Internal medicine journal.

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme

S. Vermeire, K. Subramaniam, S. Danese, 2020, Alimentary pharmacology & therapeutics.

Early predictors of colectomy and long‐term maintenance of remission in ulcerative colitis patients treated using anti‐tumour necrosis factor therapy

K. Subramaniam, B. Shadbolt, J. Platten, 2014, Internal medicine journal.

Complete resolution of recurrent calciphylaxis with long‐term intravenous sodium thiosulfate

K. Subramaniam, R. Sinniah, H. Wallace, 2008, The Australasian journal of dermatology.

Pointers and pitfalls of mycophenolate-associated colitis

K. Subramaniam, M. Kumarasinghe, W. B. de Boer, 2012, Journal of Clinical Pathology.

Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

M. Rivas, M. Daly, R. Xavier, 2019, JAMA.

AssociationofGeneticVariantsinNUDT15WithThiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease

M. Rivas, M. Daly, R. Xavier, 2019 .

Red blood cell transfusion is associated with further bleeding and fresh‐frozen plasma with mortality in nonvariceal upper gastrointestinal bleeding

J. Semmens, S. A. Mukhtar, K. Subramaniam, 2016, Transfusion.

Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.

K. Subramaniam, J. Preiß, I. Dotan, 2015, Journal of Crohn's & colitis.

Editorial: vedolizumab in inflammatory bowel diseases—less is more? Authors’ reply

K. Subramaniam, S. Danese, J. V. van Zyl, 2021, Alimentary pharmacology & therapeutics.

Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate.

K. Subramaniam, P. Pavli, M. Brown, 2011, Inflammatory bowel diseases.

Hepatosplenic T‐cell lymphoma, immunosuppressive agents and biologicals: what are the risks?

K. Subramaniam, P. Pavli, D. Talaulikar, 2014, Internal medicine journal.

Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists

K. Subramaniam, R. Bryant, B. Christensen, 2023, World journal of gastroenterology.

Histologic Remission (NANCY Index) is Superior to Endoscopic Mucosal Healing in Predicting Relapse Free Survival in Patients With Ulcerative Colitis in Clinical and Endoscopic Remission

K. Subramaniam, B. Shadbolt, P. Puri, 2019, Journal of clinical gastroenterology.

Degos' disease with delayed involvement of the gastrointestinal tract

K. Subramaniam, H. Debinski, P. Heenan, 2008, The Australasian journal of dermatology.

Glatiramer acetate induced hepatotoxicity.

K. Subramaniam, P. Pavli, H. Llewellyn, 2012, Current drug safety.

Post-colonoscopy colorectal cancers identified by probabilistic and deterministic linkage: results in an Australian prospective cohort

K. Subramaniam, D. Taupin, T. Neeman, 2019, BMJ Open.

An Extensive Review on Deep Learning and Machine Learning Intervention in Prediction and Classification of Types of Aneurysms

K. Subramaniam, Ravita Lamba, S. Muthusamy, 2023, Wireless Personal Communications.

Placental involvement by non‐Hodgkin lymphoma in a Crohn disease patient on long‐term thiopurine therapy

K. Subramaniam, P. Pavli, F. Sethna, 2016, Internal medicine journal (Print).

Red blood cell transfusion is associated with further bleeding and fresh‐frozen plasma with mortality in nonvariceal upper gastrointestinal bleeding

J. Semmens, S. A. Mukhtar, K. Subramaniam, 2016, Transfusion.

Histologic Remission (NANCY Index) is Superior to Endoscopic Mucosal Healing in Predicting Relapse Free Survival in Patients With Ulcerative Colitis in Clinical and Endoscopic Remission

K. Subramaniam, B. Shadbolt, M. Fadia, 2022, Journal of clinical gastroenterology.